Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) rises 8.9% from a year ago
Property, plant & equipment (net) stood at $11.85M at the end of Q1 FY2026, up 8.9% from a year earlier and down 8.1% from the prior quarter. Over 3 fiscal years it compounded at +237.6% a year.
Context
- Property, plant & equipment (net) amounted to 2.4% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
- Property, plant & equipment (net) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +8.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 12.89M USD
- Year-over-year change
- +159.2%
- 3-year CAGR
- +237.6%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.89M | +159.2% |
| FY2024 | 2024-12-31 | 4.97M | +24.3% |
| FY2023 | 2023-12-31 | 4M | +1094.0% |
| FY2022 | 2022-12-31 | 335K | — |
Property, Plant & Equipment (Net) vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 property, plant & equipment (net) of $11.85M is the 3rd highest of the 10 companies compared; the peer median is $6.23M.
- Its year-over-year change of +8.9% is the 4th highest of 10, against a peer median of -13.3%.
- Property, plant & equipment (net) amounts to 2.4% of total assets for RAPP, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $85.87M | +60.9% | -3.8% | 4.8% | |
| Jun 2026 | $20.03M | -13.4% | +163.4% | 2.6% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $11.85M | +8.9% | +237.6% | 2.4% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $8.07M | +31.8% | +58.8% | 3.1% |
| Mar 2026 | $6.3M | -14.0% | +57.2% | 2.3% | |
| Mar 2026 | $6.23M | -13.3% | -2.6% | 1.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3.63M | -8.3% | +975.5% | 0.9% |
| Sep 2026 | $2.58M | +380.4% | -60.5% | 0.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $390K | -79.3% | -65.0% | 0.3% |
| Mar 2026 | $326K | -48.6% | -27.5% | 0.9% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $6.23M | -13.3% | -2.6% | 1.5% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.